Aquestive Therapeutics Inc (NASDAQ:AQST) — Market Cap & Net Worth
Market Cap & Net Worth: Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc (NASDAQ:AQST) has a market capitalization of $531.98 Million ($531.98 Million) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11945 globally and #3025 in its home market, demonstrating a -9.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aquestive Therapeutics Inc's stock price $4.81 by its total outstanding shares 125466988 (125.47 Million). Also see AQST asset base for a full breakdown of the balance sheet.
Aquestive Therapeutics Inc Market Cap History: 2018 to 2026
Aquestive Therapeutics Inc's market capitalization history from 2018 to 2026. Data shows change from $790.44 Million to $603.50 Million (-13.75% CAGR). Also see Aquestive Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Aquestive Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #332 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1198 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #184 of 263 |
Weight: Aquestive Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aquestive Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aquestive Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Aquestive Therapeutics Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
18.20x
Aquestive Therapeutics Inc's market cap is 18.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $790.44 Million | $67.43 Million | -$61.38 Million | 11.72x | N/A |
| 2019 | $730.22 Million | $52.61 Million | -$66.25 Million | 13.88x | N/A |
| 2020 | $671.25 Million | $45.85 Million | -$55.78 Million | 14.64x | N/A |
| 2021 | $488.07 Million | $50.83 Million | -$70.54 Million | 9.60x | N/A |
| 2022 | $113.18 Million | $47.68 Million | -$54.41 Million | 2.37x | N/A |
| 2023 | $253.44 Million | $50.58 Million | -$7.87 Million | 5.01x | N/A |
| 2024 | $446.66 Million | $57.56 Million | -$44.14 Million | 7.76x | N/A |
| 2025 | $810.52 Million | $44.55 Million | -$83.78 Million | 18.20x | N/A |
Competitor Companies of AQST by Market Capitalization
Companies near Aquestive Therapeutics Inc in the global market cap rankings as of September 16, 2026. Review AQST tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aquestive Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Aquestive Therapeutics Inc Historical Marketcap From 2018 to 2026
Between 2018 and today, Aquestive Therapeutics Inc's market cap moved from $790.44 Million to $ 603.50 Million, with a yearly change of -13.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $603.50 Million | -25.54% |
| 2025 | $810.52 Million | +81.46% |
| 2024 | $446.66 Million | +76.24% |
| 2023 | $253.44 Million | +123.92% |
| 2022 | $113.18 Million | -76.81% |
| 2021 | $488.07 Million | -27.29% |
| 2020 | $671.25 Million | -8.08% |
| 2019 | $730.22 Million | -7.62% |
| 2018 | $790.44 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Aquestive Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $531.98 Million USD |
| MoneyControl | $531.98 Million USD |
| MarketWatch | $531.98 Million USD |
| marketcap.company | $531.98 Million USD |
| Reuters | $531.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more